Relief therapeutics « Terug naar discussie overzicht

Relief therapeutics Holding

8.803 Posts, Pagina: « 1 2 3 4 5 6 ... 413 414 415 416 417 418 419 420 421 422 423 ... 437 438 439 440 441 » | Laatste
Synopic
4
quote:

DeZwarteRidder schreef op 10 augustus 2021 10:03:


[...]

Blijkbaar heeft Relief hier weinig meer mee te maken.

Hoogstens krijgen ze nog een klein percentage.


Graag deze reactie deleten aub mod.
Duidelijke misinformatie, volgens de bestaande overeenkomst krijgen ze 50% van de net profifts.
DeZwarteRidder
0
quote:

Synopic schreef op 11 augustus 2021 15:22:


[...]Graag deze reactie deleten aub mod.
Duidelijke misinformatie, volgens de bestaande overeenkomst krijgen ze 50% van de net profifts.


Nou dan krijgen ze niks, want 'netto winst' wordt hier niet gemaakt.

Niet voor niks hebben ze ruzie met NEuroRX en met GEM>
TraceyH
7
Never gebanned..op alle fora actief als negatieve ' feedbacker'..basher en tegelijkertijd shorter. Je zou bijna zeggen...het is gewoon iemand v d IEX...zijn ' taalgebruik' zal het niet zijn . Ik ben klaar met dit forum.. tabé. Veel succes met Relief...en tegen HEM zou ik willen zeggen...veel plezier met waar je mee bezig bent, verstand van zaken...no way!
M c M
0
quote:

Balls and banger schreef op 15 augustus 2021 17:32:


Gaat dit stijgen?


Ja man, 100% zeker!

Ps, dalen ook.
Djazz
0
Weinig echt nieuws, misschien meer op de conference call straks:
NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

- Emergency Use Authorization (EUA) Request for ZYESAMI™ (aviptadil) Pending with United States Food and Drug Administration to Treat Patients Suffering from Critical COVID-19 with Respiratory Failure

- Emergency Use Authorization Granted to ZYESAMI in Nation of Georgia to Treat Critical COVID-19 Patients in July; First Orders for ZYESAMI in Georgia Under Discussion

- NRx Pharmaceuticals Initiating Phase 2b Trial in Georgia of the BriLife Vaccine for COVID, Developed in Conjunction with the Israeli Institute for Biological Research


RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a conference call Tuesday, August 17, 2021, at 8:30AM Eastern Time to discuss its business update and second quarter financial results. "NRx is pleased to report its first quarterly results as a publicly-traded company. We have continued to make substantial progress as a company with the filing of an EUA request for ZYESAMI in the US on May 31st, and the filing and granting of an EUA in the Nation of Georgia, with first orders expected shortly. We are honored to have been selected by the Israeli Institute for Biological Research to develop and market the BriLife COVID vaccine. Finally, we are looking forward to restarting trials of our psychiatry drug, NRX-101, in the coming months," said Prof Jonathan Javitt, MD, MPH, CEO and Chairman of NRx.

Business Highlights in Q2
Primary clinical activities during the quarter centered around analysis and regulatory filing of data from the phase 2b/3 trial of intravenous ZYESAMI™ for COVID-19 Respiratory Failure, support of the NIH-sponsored ACTIV3b Critical Care study of ZYESAMI compared to Veklury (remdesivir) alone and in combination, support of the BARDA-sponsored I-SPY trial of inhaled ZYESAMI, and the NRx-sponsored trial of inhaled ZYESAMI.

NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

On the manufacturing front, the Company focused on development of the first shelf-stable formulation of ZYESAMI, which was announced in early Q3, along with engagement in scaling up aviptadil drug substance from 100,000 doses per manufacturing batch to a projected 3 million doses per batch, combined with a 90% reduction in cost per gram of aviptadil drug substance.

On the business development front, NRx engaged in successful collaborative negotiations with the Israeli Institute for Biological Research (IIBR) that resulted in the long-term partnership announced in Q3. The company entered into a collaborative agreement with TFF Pharmaceuticals to develop a dry powder reconstitutable form of ZYESAMI that has now demonstrated initial room temperature stability. This technology has now shown promise for the development of a dry powder version of the BriLife vaccine. Our enthusiasm for this development project is based on nonclinical data suggesting an effective neutralizing antibody response to the Delta and other COVID variants, together with the rapidity with which this vaccine technology can be modified to cover new variants as they emerge. The company further initiated business development interactions with MannKind Corporation to leverage the Technosphere® platform for future inhaled use of ZYESAMI.

On a commercial level, the Company finalized its logistics and drug distribution contract with Cardinal Health, Inc., and its drug launch and commercialization support agreement with IQVIA, Inc. During Q2, NRx began its engagement with Georgia, Ukraine, and other countries around Emergency Use of ZYESAMI and potential clinical trials of the BriLife vaccine.

At a corporate level, much of Q2 was devoted to finalizing the business combination between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq: BRPA) that led to the creation of NRx.

Second Quarter Financial Results
NRx reported a net loss of $16.0 million for the three months ended June 30, 2021, compared to a net loss of $0.1 million for the three months ended June 30, 2020. The increase in net loss was primarily related to increases in R&D expenses, G&A expenses (which were primarily non-cash expenses associated with exercise of warrants and restructuring of the Company's Stock Option Plan) and a reduction in reimbursement of expenses from Relief Therapeutics during the second quarter of 2021 versus the prior year. Research and development expenses were $4.7 million during the three months ended June 30, 2021, compared to $1.4 million during the three months ended June 30, 2020. These costs were primarily associated with the completion of the phase 2b/3 trial of ZYESAMI. General and administrative expenses were $12.5 million for the three months ended June 30, 2021, compared to $0.5 million during the three months ended June 30, 2020. This was driven primarily by $5.5 million of consultant fees (of which $4.9 million relates to non-cash consulting fees) and $4.0 million in stock compensation expense (of which $3.3 million relates to modification of stock options and warrants due to the SPAC merger). As of June 30, 2021, cash and cash equivalents were $13.4 million, compared to $1.9 million as of December 31, 2020. In addition, NRx received $9.2 million subsequent to June 30, 2021 from the exercise of warrants.

As stated in the 10-Q filing, NRx has sufficient core operating funds to support operations through the next 12 months. Clinical trial operations for ACTIV3b and I-SPY are primarily funded by the US Government. We anticipate that the BriLife vaccine development program will be co-funded by a commercial partner with additional partnerships in development.

Conference Call and Webcast Information
NRx will host a conference call and webcast on August 17, 2021 8:30 AM Eastern Time to discuss its results and provide a clinical and corporate update. Management will host the call, followed by a question-and-answer period. Analysts and investors interested in submitting questions must do so in advance of the call,and are encouraged to email questions to the Company's investor relations representative at jmullaly@lifesciadvisors.com.

Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes prior to the start of the call by dialing (877) 705-6003 (U.S.), (201) 493-6725 (International) Conference ID: 13722418, or through the webcast link public.viavid.com/index.php?id=146267. A replay will be available from the NRx Pharmaceuticals website following the call at www.nrxpharma.com.

Volledig artikel: www.prnewswire.com/news-releases/nrx-...
User133
0
quote:

Djazz schreef op 17 augustus 2021 09:13:


Weinig echt nieuws, misschien meer op de conference call straks:
NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

- Emergency Use Authorization (EUA) Request for ZYESAMI™ (aviptadil) Pending with United States Food and Drug Administration to Treat Patients Suffering from Critical COVID-19 with Respiratory Failure

- Emergency Use Authorization Granted to ZYESAMI in Nation of Georgia to Treat Critical COVID-19 Patients in July; First Orders for ZYESAMI in Georgia Under Discussion

- NRx Pharmaceuticals Initiating Phase 2b Trial in Georgia of the BriLife Vaccine for COVID, Developed in Conjunction with the Israeli Institute for Biological Research


RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a conference call Tuesday, August 17, 2021, at 8:30AM Eastern Time to discuss its business update and second quarter financial results. "NRx is pleased to report its first quarterly results as a publicly-traded company. We have continued to make substantial progress as a company with the filing of an EUA request for ZYESAMI in the US on May 31st, and the filing and granting of an EUA in the Nation of Georgia, with first orders expected shortly. We are honored to have been selected by the Israeli Institute for Biological Research to develop and market the BriLife COVID vaccine. Finally, we are looking forward to restarting trials of our psychiatry drug, NRX-101, in the coming months," said Prof Jonathan Javitt, MD, MPH, CEO and Chairman of NRx.

Business Highlights in Q2
Primary clinical activities during the quarter centered around analysis and regulatory filing of data from the phase 2b/3 trial of intravenous ZYESAMI™ for COVID-19 Respiratory Failure, support of the NIH-sponsored ACTIV3b Critical Care study of ZYESAMI compared to Veklury (remdesivir) alone and in combination, support of the BARDA-sponsored I-SPY trial of inhaled ZYESAMI, and the NRx-sponsored trial of inhaled ZYESAMI.

NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

On the manufacturing front, the Company focused on development of the first shelf-stable formulation of ZYESAMI, which was announced in early Q3, along with engagement in scaling up aviptadil drug substance from 100,000 doses per manufacturing batch to a projected 3 million doses per batch, combined with a 90% reduction in cost per gram of aviptadil drug substance.

On the business development front, NRx engaged in successful collaborative negotiations with the Israeli Institute for Biological Research (IIBR) that resulted in the long-term partnership announced in Q3. The company entered into a collaborative agreement with TFF Pharmaceuticals to develop a dry powder reconstitutable form of ZYESAMI that has now demonstrated initial room temperature stability. This technology has now shown promise for the development of a dry powder version of the BriLife vaccine. Our enthusiasm for this development project is based on nonclinical data suggesting an effective neutralizing antibody response to the Delta and other COVID variants, together with the rapidity with which this vaccine technology can be modified to cover new variants as they emerge. The company further initiated business development interactions with MannKind Corporation to leverage the Technosphere® platform for future inhaled use of ZYESAMI.

On a commercial level, the Company finalized its logistics and drug distribution contract with Cardinal Health, Inc., and its drug launch and commercialization support agreement with IQVIA, Inc. During Q2, NRx began its engagement with Georgia, Ukraine, and other countries around Emergency Use of ZYESAMI and potential clinical trials of the BriLife vaccine.

At a corporate level, much of Q2 was devoted to finalizing the business combination between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq: BRPA) that led to the creation of NRx.

Second Quarter Financial Results
NRx reported a net loss of $16.0 million for the three months ended June 30, 2021, compared to a net loss of $0.1 million for the three months ended June 30, 2020. The increase in net loss was primarily related to increases in R&D expenses, G&A expenses (which were primarily non-cash expenses associated with exercise of warrants and restructuring of the Company's Stock Option Plan) and a reduction in reimbursement of expenses from Relief Therapeutics during the second quarter of 2021 versus the prior year. Research and development expenses were $4.7 million during the three months ended June 30, 2021, compared to $1.4 million during the three months ended June 30, 2020. These costs were primarily associated with the completion of the phase 2b/3 trial of ZYESAMI. General and administrative expenses were $12.5 million for the three months ended June 30, 2021, compared to $0.5 million during the three months ended June 30, 2020. This was driven primarily by $5.5 million of consultant fees (of which $4.9 million relates to non-cash consulting fees) and $4.0 million in stock compensation expense (of which $3.3 million relates to modification of stock options and warrants due to the SPAC merger). As of June 30, 2021, cash and cash equivalents were $13.4 million, compared to $1.9 million as of December 31, 2020. In addition, NRx received $9.2 million subsequent to June 30, 2021 from the exercise of warrants.

As stated in the 10-Q filing, NRx has sufficient core operating funds to support operations through the next 12 months. Clinical trial operations for ACTIV3b and I-SPY are primarily funded by the US Government. We anticipate that the BriLife vaccine development program will be co-funded by a commercial partner with additional partnerships in development.

Conference Call and Webcast Information
NRx will host a conference call and webcast on August 17, 2021 8:30 AM Eastern Time to discuss its results and provide a clinical and corporate update. Management will host the call, followed by a question-and-answer period. Analysts and investors interested in submitting questions must do so in advance of the call,and are encouraged to email questions to the Company's investor relations representative at jmullaly@lifesciadvisors.com.

Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes prior to the start of the call by dialing (877) 705-6003 (U.S.), (201) 493-6725 (International) Conference ID: 13722418, or through the webcast link public.viavid.com/index.php?id=146267. A replay will be available from the NRx Pharmaceuticals website following the call at www.nrxpharma.com.

Volledig artikel: www.prnewswire.com/news-releases/nrx-...


Ik vind de details in de Q10 wel zorgwekkend - alles duidt erop dat NRX gaat claimen dat de nieuwe formule hun verdienste is en dat Relief geen recht heeft op een profit share omdat ze het niet gefund hebben. Of de boel wordt opengebroken en heronderhandeld of er komt een rechtzaak m.i.

Ben benieuwd naar de conference call.
DeZwarteRidder
0
quote:

User133 schreef op 17 augustus 2021 09:21:


[...]Ik vind de details in de Q10 wel zorgwekkend - alles duidt erop dat NRX gaat claimen dat de nieuwe formule hun verdienste is en dat Relief geen recht heeft op een profit share omdat ze het niet gefund hebben. Of de boel wordt opengebroken en heronderhandeld of er komt een rechtzaak m.i.
Ben benieuwd naar de conference call.


En wie heeft hiervoor allang gewaarschuwd....???

Juist ja.........!!!!
Reader
0
quote:

DeZwarteRidder schreef op 17 augustus 2021 09:26:


[...]

En wie heeft hiervoor allang gewaarschuwd....???

Juist ja.........!!!!



Tja...ik ben haar naam even kwijt, wel een hele slimme dame!
eric_k4
1
Ja, nu weet ik het weer., haar naam is Gebreille Milene Puttie Janie Metalivry Dourariere de Puttens van Gisterens to Hiero en niette Verderro, ze had een bastaard oom geheten Blikken Toonie sonder Paert ende Verstand, die bij gans en wijle gerne opdraefde,, zich hullende in blicken en roestende malienkolder en blaetende "icke heb gelijk, so niets verhulle zijne naekende en vetten anblick, sodat een elks blick sich afwende van seine ongelijk,...
DeZwarteRidder
0
quote:

eric_k4 schreef op 17 augustus 2021 19:19:


Ja, nu weet ik het weer., haar naam is Gebreille Milene Puttie Janie Metalivry Dourariere de Puttens van Gisterens to Hiero en niette Verderro, ze had een bastaard oom geheten Blikken Toonie sonder Paert ende Verstand, die bij gans en wijle gerne opdraefde,, zich hullende in blicken en roestende malienkolder en blaetende "icke heb gelijk, so niets verhulle zijne naekende en vetten anblick, sodat een elks blick sich afwende van seine ongelijk,...


Je klinkt als een boer met kiespijn.
Reader
0
quote:

eric_k4 schreef op 17 augustus 2021 19:19:


Ja, nu weet ik het weer., haar naam is Gebreille Milene Puttie Janie Metalivry Dourariere de Puttens van Gisterens to Hiero en niette Verderro, ze had een bastaard oom geheten Blikken Toonie sonder Paert ende Verstand, die bij gans en wijle gerne opdraefde,, zich hullende in blicken en roestende malienkolder en blaetende "icke heb gelijk, so niets verhulle zijne naekende en vetten anblick, sodat een elks blick sich afwende van seine ongelijk,...


'Teen ent 'tander ter leering ende vermaeck, also sprach erne.
Djazz
0
Aandelen 50/50 in NRXP en RLF: tweetrapsraket (als 'm afgaat) in mijn gokafdeling van de portefeuille. De andere is LWLG, bij deze een gratis tip: wel meer een langeafstandsraket.
Djazz
1
Nog eens wat (goed!) nieuws posten ook:

www.prnewswire.com/news-releases/nrx-...

NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19
- After Review of Approximately 140 patients in ACTIV-3 Critical Care Study, No New Safety Concerns Raised by Independent Data Safety Monitoring Board, Study to Continue Enrollment to Target More than 600 Patients

- ACTIV-3 Critical Care is a Public-Private Partnership Sponsored by the US National Institutes of Health to Treat COVID-19

- ACTIV-3 Critical Care is Evaluating ZYESAMI™ and Remdesivir, in Critical COVID-19 Patients, as Monotherapy and in Combination Against Placebo


(PRNewsfoto/NeuroRx)
NEWS PROVIDED BY

NRx Pharmaceuticals
Aug 18, 2021, 11:53 ET

SHARE THIS ARTICLE

RADNOR, Pa., Aug. 18, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI™ (aviptadil) which is being tested in the ACTIV-3 Critical Care Phase 3 study sponsored by the National Institutes of Health. The study's Data Safety Monitoring Board found no new safety concerns in the trial and recommended continued enrollment.

ACTIV-3 is a randomized, blinded, placebo-controlled clinical trial testing ZYESAMI™ and the antiviral remdesivir (Veklury) in hospitalized patients with acute respiratory failure due to COVID-19 who require high-flow supplemental oxygen, delivered by nasal cannula, mechanical ventilation, or extracorporeal membrane oxygenation.

After Review of Approximately 140 patients, No New Safety Concerns Raised by Independent Data Safety Monitoring Board

Study investigators are randomizing patients to receive one of four treatment regimens in addition to standard of care: both ZYESAMI™ and remdesivir, ZYESAMI™ and a placebo, remdesivir and placebo, or only placebo. ZYESAMI™ is administered as a daily 12 hour intravenous infusion over three days. Those randomized to receive remdesivir will receive it for up to 10 days via intravenous infusion.

ZYESAMI™ (aviptadil) is a proprietary, synthetic version of Vasoactive Intestinal Peptide or VIP, which is made naturally in the human body and appears to have lung-protective, anti-viral and anti-inflammatory effects.

ACTIV-3 represents one of three ongoing studies of ZYESAMI™ in Severe or Critical COVID-19.

About NRx Pharmaceuticals
NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific and drug-development experience to bring improved health to patients. Its investigational product, ZYESAMI™ (aviptadil) for patients with COVID-19, has been granted Fast Track designation by the US Food and Drug Administration (FDA) and is currently undergoing phase 3 trials funded by the US National Institutes of Health, the Biomedical Advanced Research and Development Authority part of the US Department of Health and Human Services, and the Medical Countermeasures program, part of the US Department of Defense. The FDA has additionally granted Breakthrough Therapy Designation, a Special Protocol Agreement, and a Biomarker Letter of Support to NRx for NRX-101, an investigational medicine to treat suicidal bipolar depression. NRX-101 is currently in Phase 3 trials, with readouts expected in 2022. In July 2021, the Government of Israel awarded NRx the exclusive worldwide right to develop and market the BriLife™ COVID vaccine developed by the Israel Institute for Biological Research.

NRx is led by executives who have held senior roles at Allergan, J&J, Lilly, Novartis, Pfizer, and the US FDA. NRx is chaired by Prof Jonathan Javitt, MD, MPH, who has held leadership roles in six biotechnology startup companies with public exits and been appointed to advisory roles in four US Presidential Administrations. The NRx board includes Dr. Sherry Glied, former US Assistant Secretary for Health (ASPE), Daniel E. Troy, JD, former Chief Counsel of the US FDA, Chaim Hurvitz, former director of Teva and President of the Teva International Group, and General H.R. McMaster, Ph.D. (US Army, Ret.) the 26th United States National Security Advisor.

Cautionary Note Regarding Forward-Looking Statements
This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the company's strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the company's management.

The company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.
DeZwarteRidder
0
Het schiet allemaal lekker op; nog even en aviptadil is volkomen achterhaald en overbodig.
Rotmeo
1
- After Review of Approximately 140 patients in ACTIV-3 Critical Care Study, No New Safety Concerns Raised by Independent Data Safety Monitoring Board, Study to Continue Enrollment to Target More than 600 Patients

- ACTIV-3 Critical Care is a Public-Private Partnership Sponsored by the US National Institutes of Health to Treat COVID-19

- ACTIV-3 Critical Care is Evaluating ZYESAMI™ and Remdesivir, in Critical COVID-19 Patients, as Monotherapy and in Combination Against Placebo
DeZwarteRidder
0
quote:

Rotmeo schreef op 19 augustus 2021 08:48:


- After Review of Approximately 140 patients in ACTIV-3 Critical Care Study, No New Safety Concerns Raised by Independent Data Safety Monitoring Board, Study to Continue Enrollment to Target More than 600 Patients

- ACTIV-3 Critical Care is a Public-Private Partnership Sponsored by the US National Institutes of Health to Treat COVID-19

- ACTIV-3 Critical Care is Evaluating ZYESAMI™ and Remdesivir, in Critical COVID-19 Patients, as Monotherapy and in Combination Against Placebo


Dit gaat nog wel een paar jaar duren.
eric_k4
1
In ieder geval veel minder lang dan jouw jarenlang negatief gedrag op de vele IEX forums...
BorisK.
1
Sonnet Bioth. staat +64% voorbeurs in de VS, op het moment dat ik dit schrijf, zojuist was het nog 23%. En nu al in de 80% .... .

Dochtermaatschappij: Relief Th.

Voor wat het waard is voor zover deze 2 feiten verband houden.

P.S. net terug van lange vakantie, dus ben niet echt verder op de hoogte wat reilt en zeilt op de beurs, hierbij het excuus als dit schot in de mist is.
8.803 Posts, Pagina: « 1 2 3 4 5 6 ... 413 414 415 416 417 418 419 420 421 422 423 ... 437 438 439 440 441 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 29 nov 2021 17:31
Koers 0,067
Verschil +0,009 (+15,86%)
Hoog 0,073
Laag 0,053
Volume 56.815.167
Volume gemiddeld 22.934.271
Volume gisteren 20.229.658

Brussel real time stocks quotedata by Euronext. Other real time EU stocks, by Cboe Europe Ltd.; US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront